AR040549A1 - Moduladores ureicos derivados de naftol, quinolina e isoquinolina del receptor vainilloide vr1. - Google Patents

Moduladores ureicos derivados de naftol, quinolina e isoquinolina del receptor vainilloide vr1.

Info

Publication number
AR040549A1
AR040549A1 AR20030102512A ARP030102512A AR040549A1 AR 040549 A1 AR040549 A1 AR 040549A1 AR 20030102512 A AR20030102512 A AR 20030102512A AR P030102512 A ARP030102512 A AR P030102512A AR 040549 A1 AR040549 A1 AR 040549A1
Authority
AR
Argentina
Prior art keywords
alkanyl
group
alkyloxy
fluorinated
alkylamino
Prior art date
Application number
AR20030102512A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR040549A1 publication Critical patent/AR040549A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Está dirigida a ligados VR1 receptores vainilloides. Mas particularmente, se refiere a ureas derivadas de naftol, quinolina e isoquinolina que son potentes antagonistas o agonistas de VR1 que son útiles para el tratamiento y prevención de estados inflamatorios y de otros trastornos dolorosos en mamíferos. Reivindicación 1: Una composición que comprende un compuesto de fórmula (1): en la cual: R1 y R2 sin sustituyentes independientemente seleccionados del grupo que consiste en hidrógeno; hidroxi; halógeno; alcanilo C1-8 opcionalmente sustituido con uno o más sustituyentes independientemente seleccionados del grupo que consiste en halógeno, alcanilo fluorado y alcaniloxi C1-8; alcaniloxi C1-8 opcionalmente sustituido con uno o más sustituyentes independientemente seleccionados del grupo que consiste en halógeno, alcanilo fluorado y alcaniloxi C1-8; alcaniloxi fluorado; alcanilo fluorado; alcaniltio C1-8 opcionalmente sustituido con uno o más sustituyentes independientemente seleccionados del grupo que consiste en halógeno, alcanilo fluorado y alcaniloxi C1-8; cicloalcanilo C3-8; cicloalcaniloxi C3-8; nitro, amino; alcanilamino C1-8; dialcanilamino C1-8; cicloalcanilamino C3-8; ciano; carboxi; alcaniloxicarbonilo C1-7; alcanilcarboniloxi C1-7; alcanilaminocarbonilo C1-7, alcanilcarbonilamino C1-7, diC1-7alcanilaminocarbonilo y formilo; R3 está independientemente seleccionado del grupo que consiste en hidrógeno; hidroxi; flúor; cloro; nitro; amino; alcanilamino C1-8, y dialcanilamino C1-8; L es un alquildiilo C1-4 opcionalmente sustituido con un sustituyente seleccionado del grupo que consiste en alcanilo C1-8, cicloalcanilo C3-8 y fenilo opcionalmente sustituido con uno a tres sustituyentes independientemente seleccionado del grupo que consiste en alcanilo C1-8, halógeno, alcaniloxi C1-8, hidroxi, alcanilo fluorado, alcaniloxi fluorado, amino, di(C1-3)alcanilamino, y alcanilamino C1-3; R4 está seleccionado del grupo que consiste en hidrógeno y alcanilo C1-3, R5 está seleccionado del grupo que consiste en hidrógeno y alcanilo C1-3, R6 está seleccionado del grupo que consiste en fenilo sustituido con uno a tres sustituyentes independientes seleccionados del grupo que consiste en alcanilo C1-8, cicloalcanilo C3-8, halógeno, alcaniloxi C1-8, hidroxi, alcanilo fluorado, alcaniloxi fluorado, nitro, amino, di(C1-8)alcanilamino, alcanilamino C1-8, aminosulfonilo, alcanilaminosulfonilo C1-8, di(C1-8)alcanilaminosulfonilo y ciano; naftilo opcionalmente sustituido con uno a tres sustituyentes independientemente seleccionados del grupo que consiste en alcanilo C1-8, halógeno, alcaniloxi C1-8, hidroxi, alcanilo fluorado, alcaniloxi fluorado, nitro, amino, di(C1-8)alcanilamino, alcanilamino C1-8, aminosulfonilo, alcanilaminosulfonilo C1-8, di(C1-8)alcanilaminosulfonilo y ciano; heteroarilo opcionalmente sustituido con uno o dos sustituyentes seleccionados del grupo que consiste en alcanilo C1-8, halógeno, alcaniloxi C1-8, hidroxi, alcanilofluorado, y alcaniloxi fluorado donde dicho heteroarilo es tienilo, furanilo, benzotienilo, benzofuranilo, piridilo o bencimidazol; cicloalcanilo C5-7 opcionalmente sustituido con alcanilo C1-6, y heteroalcanilo cíclico seleccionado del grupo que consiste en morfolinilo, piperazinilo, piperidinilo, imidazolidinilo, pirazolidinilo, tiomorfolinilo, y pirrolidinilo; X está seleccionado entre C-H, N y N-> O; Y es C o N, con la condición de que si Y es N entonces R3 está ausente;: Z está seleccionado del grupo que consiste en O y S; y los enantiómeros, diastereómeros, tautómeros, solvatos y sus sales farmacéuticamente aceptables.
AR20030102512A 2002-07-12 2003-07-11 Moduladores ureicos derivados de naftol, quinolina e isoquinolina del receptor vainilloide vr1. AR040549A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39572802P 2002-07-12 2002-07-12
US39595102P 2002-07-15 2002-07-15

Publications (1)

Publication Number Publication Date
AR040549A1 true AR040549A1 (es) 2005-04-13

Family

ID=30118539

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030102512A AR040549A1 (es) 2002-07-12 2003-07-11 Moduladores ureicos derivados de naftol, quinolina e isoquinolina del receptor vainilloide vr1.

Country Status (6)

Country Link
US (1) US7183411B2 (es)
AR (1) AR040549A1 (es)
AU (1) AU2003251828A1 (es)
CL (1) CL2003001415A1 (es)
TW (1) TW200410941A (es)
WO (1) WO2004007459A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1569896B1 (en) * 2002-12-06 2007-08-15 Bayer HealthCare AG Tetrahydro-naphthalene derivatives
CA2508845C (en) * 2002-12-09 2012-02-21 Bayer Healthcare Ag Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists
JP4943837B2 (ja) 2003-04-03 2012-05-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 可溶性エポキシド加水分解酵素の改良インヒビター
EP1679296A4 (en) 2003-10-14 2007-12-26 Ajinomoto Kk DERIVE ETHERE
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
RU2403247C2 (ru) * 2004-07-20 2010-11-10 СЬЕНА БИОТЕК С.п.А. Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения
ZA200703613B (en) 2004-10-20 2009-05-27 Univ California Improved inhibitors for the soluble epoxide hydrolase
JP5159604B2 (ja) * 2005-03-19 2013-03-06 アモーレパシフィック コーポレイション バニロイド受容体拮抗薬としての新規な化合物、その異性体又はその薬剤学的に許容される塩、及びこれを含む医薬組成物
AR059826A1 (es) * 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
GB0611417D0 (en) * 2006-06-09 2006-07-19 Leuven K U Res & Dev Treatment of cndaria intoxication
TW200901974A (en) * 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
WO2009073788A1 (en) * 2007-12-07 2009-06-11 Firestone Leigh H Compositions and methods for treating menopausal females
JP5685203B2 (ja) * 2009-05-29 2015-03-18 ラクオリア創薬株式会社 カルシウムチャネル遮断薬またはナトリウムチャネル遮断薬としてのアリール置換カルボキサミド誘導体
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
AR097279A1 (es) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd Derivados de benzimidazolil-metil urea como agonistas del receptor de alx
JP6746614B2 (ja) * 2015-05-27 2020-08-26 杏林製薬株式会社 ウレア誘導体、またはその薬理学的に許容される塩
CN105906564B (zh) * 2016-05-05 2018-11-30 海南省药物研究所 化合物、制备方法及其用途
WO2022030589A1 (ja) * 2020-08-05 2022-02-10 国立大学法人北海道大学 単座配位尿素化合物を含む配位子とそれを含むホウ素化触媒
WO2022058327A1 (en) * 2020-09-15 2022-03-24 Bayer Aktiengesellschaft Substituted ureas and derivatives as new antifungal agents
IL309232A (en) 2021-06-14 2024-02-01 Scorpion Therapeutics Inc History of urea which can be used to treat cancer
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4008326A (en) * 1973-12-26 1977-02-15 The Upjohn Company Substituted ureas and thioureas and pharmaceutical compositions thereof
WO1991004027A1 (en) * 1989-09-15 1991-04-04 Pfizer Inc. New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat)
US5362878A (en) * 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
US5610192A (en) 1992-09-11 1997-03-11 The Regents Of The University Of California Inhibitors of metazoan parasite proteases
JP2003500382A (ja) 1999-05-24 2003-01-07 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子の阻害剤
MXPA03000458A (es) 2000-07-20 2004-06-02 Neurogen Corp Ligandos receptores de capsaicina.
NZ523882A (en) 2000-08-21 2004-11-26 Pacific Corp Novel thiourea derivatives and the pharmaceutical compositions containing the same
WO2002016319A1 (en) 2000-08-21 2002-02-28 Pacific Corporation Novel thiourea compounds and the pharmaceutical compositions containing the same
AU2001278821A1 (en) * 2000-08-21 2002-03-04 Pacific Corporation Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same
JP2005501873A (ja) * 2001-07-31 2005-01-20 バイエル・ヘルスケア・アクチェンゲゼルシャフト アミン誘導体
GB0130550D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel compounds
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
MXPA04008073A (es) * 2002-02-20 2004-11-26 Abbott Lab Compuestos azabiciclicos fusionados que inhiben el receptor de subtipo 1 (vr1) del receptor de vainilloide.
GB0206876D0 (en) 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
WO2004007459A3 (en) 2004-03-18
AU2003251828A8 (en) 2004-02-02
US20040157865A1 (en) 2004-08-12
US7183411B2 (en) 2007-02-27
AU2003251828A1 (en) 2004-02-02
WO2004007459A2 (en) 2004-01-22
CL2003001415A1 (es) 2005-01-07
TW200410941A (en) 2004-07-01

Similar Documents

Publication Publication Date Title
AR040549A1 (es) Moduladores ureicos derivados de naftol, quinolina e isoquinolina del receptor vainilloide vr1.
AR039823A1 (es) Moduladores ureicos derivados de la amino-tetralina del receptor vr1 de vanilloides
CY1109015T1 (el) Διφαινυλ ενωσεις χρησιμες ως ανταγωνιστες μουσκαρινικου υποδοχεα
EA200301073A1 (ru) N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
UY29081A1 (es) Compuestos de aminoheteroarilo enantioméricamente puros como inhibidores de proteína quinasa
AR043015A1 (es) Compuestos moduladores de amida derivada de quinolina del receptor vanilloide vr1, composiciones farmaceuticas y veterinarias que los contienen y su uso en el tratamiento de enfermedades afectadas por la modulacion de dichos receptores
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
YU37904A (sh) Benzimidazoli kao korisni inhibitori proteinske kinaze
SE0303180D0 (sv) Novel compounds
DE602006007556D1 (de) Heteroarylsulfonylstilbene als 5-ht2a-antagonisten
RS52715B (en) HYDROXYBENZAMIDE DERIVATIVES AND THEIR APPLICATIONS AS HSP90 INHIBITORS
PA8546601A1 (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6
PE20091093A1 (es) Compuesto heterociclico que contiene nitrogeno y su uso
NO20061981L (no) Arylindenopyridiner og arylindenopyridiner og deres anvendelse som adenosin A2A reseptoragonist
EA200601141A1 (ru) Сульфонамидные производные для лечения заболеваний
DE602004027021D1 (de) Cgrp-rezeptorantagonisten
DE602005027230D1 (de) Cgrp-rezeptorantagonisten
EA200900337A1 (ru) Сульфонамидные производные в качестве адренергических агонистов и мускариновых антагонистов
ATE399770T1 (de) Tachykininrezeptorantagonisten
DK0923581T3 (da) 4-substituerede beta-carboliner som immunmodulatorer
PE20060770A1 (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1
EA200970704A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТАГОНИСТЫ NK1 РЕЦЕПТОРА И БЛОКАТОРЫ Na КАНАЛОВ
DE602006014097D1 (de) Cgrp-rezeptorantagonisten
AR087354A1 (es) Inhibidores selectivos de la proteina quinasa

Legal Events

Date Code Title Description
FB Suspension of granting procedure